TY - JOUR T1 - The role of hippocampal theta oscillations in working memory impairment in multiple sclerosis JF - medRxiv DO - 10.1101/2020.06.15.20127191 SP - 2020.06.15.20127191 AU - Lars Costers AU - Jeroen Van Schependom AU - Jorne Laton AU - Johan Baijot AU - Martin Sjøgård AU - Vincent Wens AU - Xavier De Tiège AU - Serge Goldman AU - Miguel D’Haeseleer AU - Marie Beatrice D’hooghe AU - Mark Woolrich AU - Guy Nagels Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/16/2020.06.15.20127191.abstract N2 - Working memory (WM) problems are frequent in persons with multiple sclerosis (MS). Even though hippocampal damage has been repeatedly shown to play an important role, the underlying neurophysiological mechanisms remain unclear. This study aimed to investigate the neurophysiological underpinnings of WM impairment in MS using magnetoencephalography (MEG) data from a verbal n-back task. We analysed MEG recordings of 79 MS patients and 38 healthy subjects through event-related fields (ERFs) and theta (4-8 Hz) and alpha (8-13 Hz) oscillatory processes. Data was source reconstructed and parcellated based on previous findings in the healthy subject sample. MS patients showed a smaller maximum theta power increase in the right hippocampus between 0 and 400 ms than healthy subjects (p = 0.014). This theta power increase value correlated strongly and negatively with reaction time on the task in MS (r = −0.32, p = 0.029). Evidence was provided that this relationship could not be explained by a confounding relationship with MS-related neuronal damage. This study provides the first neurophysiological evidence of the influence of hippocampal dysfunction on WM performance in MS.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02851342Funding StatementBelgian Charcot Foundation; Fond Erasme pour la Recherche Medicale; Fondation Philippe Wiener - Maurice Anspach; Fonds De La Recherche Scientifique - FNRS; Fonds Erasme; Fonds Wetenschappelijk Onderzoek, Grant/Award Numbers: 11B7218N, 12I1817N, 1501218N, 1805620N; GenzymeAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study was provided by the ethics committees of the National MS Center Melsbroek (2015-02-12) and the University Hospital Brussels (Commissie Medische Ethiek UZ Brussel, B.U.N. 143201423263, 2015/11).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data for this study are not publicly available. Researchers interested in a collaboration on these data are welcome to contact the senior authors. Analysis scripts are available upon request from the corresponding author. ER -